Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $2,501,637.36 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard Geary sold 33,038 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $75.72, for a total transaction of $2,501,637.36. Following the transaction, the executive vice president directly owned 59,657 shares in the company, valued at $4,517,228.04. This trade represents a 35.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ionis Pharmaceuticals Stock Down 0.7%

IONS stock traded down $0.55 during trading on Friday, reaching $73.55. 2,332,340 shares of the stock were exchanged, compared to its average volume of 1,971,165. The firm’s 50 day moving average is $66.49 and its 200 day moving average is $47.79. The firm has a market cap of $11.91 billion, a P/E ratio of -43.52 and a beta of 0.33. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $76.78.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.The firm had revenue of $157.00 million during the quarter, compared to the consensus estimate of $131.75 million. During the same quarter in the previous year, the company posted ($0.95) earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Significant Wealth Partners LLC raised its position in Ionis Pharmaceuticals by 24.8% in the first quarter. Significant Wealth Partners LLC now owns 13,605 shares of the company’s stock worth $410,000 after acquiring an additional 2,700 shares during the period. Xponance Inc. increased its stake in shares of Ionis Pharmaceuticals by 5.1% during the 1st quarter. Xponance Inc. now owns 20,319 shares of the company’s stock worth $613,000 after purchasing an additional 980 shares during the last quarter. CWM LLC increased its stake in shares of Ionis Pharmaceuticals by 18.7% during the 1st quarter. CWM LLC now owns 2,435 shares of the company’s stock worth $73,000 after purchasing an additional 384 shares during the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Ionis Pharmaceuticals by 31.5% in the 1st quarter. Bleakley Financial Group LLC now owns 22,284 shares of the company’s stock worth $672,000 after purchasing an additional 5,342 shares during the period. Finally, Signaturefd LLC lifted its stake in Ionis Pharmaceuticals by 45.6% in the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after purchasing an additional 433 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IONS. Oppenheimer boosted their target price on shares of Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 8th. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research note on Monday, October 6th. BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $40.00 to $70.00 in a research report on Wednesday, September 3rd. Finally, JPMorgan Chase & Co. upgraded Ionis Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $49.00 to $80.00 in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $83.65.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.